Clinical Trial Detail

NCT ID NCT02595866
Title Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Hodgkin's lymphoma

Kaposi's sarcoma

non-Hodgkin lymphoma

hepatocellular carcinoma

Advanced Solid Tumor

melanoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.